◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Medicenna Therapeutics Corp. (MDNA) Financial History

Name: Medicenna Therapeutics Corp. (MDNA) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-08-16

Medicenna Therapeutics Corp. (MDNA) operates in the Biotechnology industry and is headquartered in Toronto, Canada with about 15 employees. Its market capitalization is roughly CAD 42 million. In the fiscal year ended 2026-03-31, MDNA reported CAD 0M in revenue and (CAD 18M) in net income.

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases.

Interactive charts & full statements →

MDNA Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Revenue	CAD 0M	CAD 0M	CAD 0M	CAD 0M	—
Operating Income (EBIT)	(CAD 22M)	(CAD 20M)	(CAD 19M)	(CAD 16M)	—
Net Income	(CAD 18M)	(CAD 12M)	(CAD 26M)	(CAD 10M)	—

CAD; CADM / CADB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MDNA Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31
Total Revenue	CAD 0M	CAD 0M	CAD 0M	CAD 0M	CAD 0M	—
Operating Income (EBIT)	(CAD 6M)	(CAD 6M)	(CAD 6M)	(CAD 6M)	(CAD 6M)	—
Net Income	(CAD 4M)	(CAD 4M)	(CAD 5M)	(CAD 5M)	CAD 1M	—

CAD; CADM / CADB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MDNA Free Cash Flow History

MDNA Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	CAD 8M	CAD 28M	CAD 19M	CAD 36M	—
Total Liabilities	CAD 6M	CAD 9M	CAD 14M	CAD 7M	—

CAD; CADM / CADB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive MDNA viewer.

Other Companies in Biotechnology

MGX · Metagenomi Therapeutics, Inc. — $46 million
VERU · Veru Inc. — $46 million
KPTI · Karyopharm Therapeutics Inc. — $46 million
MCRB · Seres Therapeutics, Inc. — $46 million
CRVO · CervoMed Inc. — $41 million
HEMO · Hemogenyx Pharmaceuticals Plc — $41 million
BCT · BriaCell Therapeutics Corp. — $41 million
HYPD · Hyperion DeFi, Inc. — $41 million

← MDM All “M” companies MDP →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.